Celularity Incorporated
Clinical trials sponsored by Celularity Incorporated, explained in plain language.
A clinical-stage biotechnology company developing allogeneic cell therapies from placental stem cells.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Placenta cells tested as COVID fighter – but trial stopped early
Disease control Stopped earlyThis early-phase trial tested a new therapy called CYNK-001, which uses natural killer cells from the placenta to fight COVID-19. It enrolled only 7 adults with moderate COVID-19. The study was terminated early, so we have limited information on safety and effectiveness.
Phase 1/2 • Sponsor: Celularity Incorporated • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Placenta power: could donor cells heal diabetic foot wounds?
Disease control Stopped earlyThis study tests whether injections of cells from donated human placentas can help heal foot ulcers in people with diabetes. The trial includes patients with and without peripheral artery disease, a common complication that slows healing. Participants receive either the cell trea…
Phase 2 • Sponsor: Celularity Incorporated • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC